How did Biocon disrupt the recombinant human insulin market in India?
Replied byKiran Mazumdar-Shaw
Founder & Executive Chairperson at Biocon
Niche: Health & Wellness
Revenue: Approx. $172 Million/month
Location: Bengaluru, Karnataka, India
Started: 1978
Recombinant human insulin was imported by Western multinationals who sold it at one thousand rupees per vial. We used a recombinant DNA technology based on Pichia yeast to produce human insulin domestically, dropping the price to one hundred rupees and forcing competitors to match us.
0
From the Full Interview
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Share this Answer
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Cite This Answer
Use this answer in your research, article, or academic work
Related Answers
Why are declared goals more powerful for human motivation than undeclared ones?
By Adrian Gore
Health & Wellness
Approx. 400 Million/mo
What challenges did you face when trying to enter the brewing industry in India?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did you choose to bypass the Indian market for your first GLP-1 drug launch?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
Why did the market react skeptically to your acquisition of Viatris's biosimilar assets?
By Kiran Mazumdar-Shaw
Health & Wellness
Approx. $172 Million/mo
How has the ACA market evolved over the years?
By Mark Bertolin
Health & Wellness
$500M+/mo
How did walking into the gym at age seventeen change the trajectory of your life?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo
What inspired you to start posting fitness videos online and how did that evolve?
By Krissy Cela
Health & Wellness
Approx. 16.6 Million USD/mo